The Insider Activity Of Viking Therapeutics Inc. (VKTX) Is Worth Monitoring

0
95

Viking Therapeutics Inc. (NASDAQ:VKTX) finished Thursday with an addition of $0.33 to close at $9.32, an upside of 3.67 percent. An average of 5,298,100 shares of common stock have been traded in the last five days. There was a gain of $1.43 in the past week, and it reached a new high 10 times over the past 12 months. The last 20 days have seen an average of 8,205,405 shares traded, while the 50-day average volume stands at 3,849,772.

VKTX stock has increased by 136.55% in the last month. The company shares reached their 1-month lowest point of $3.54 on 12/12/22. With the stock rallying to its 52-week high on 12/29/22, shares of the company touched a low of $2.02 and a high of $9.04 in 52 weeks. It has reached a new high 9 times so far this year and achieved 102.61% or $4.72 in price. In spite of this, the price is up 3.10% from the 52-week high.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Valuation Metrics

Viking Therapeutics Inc. (VKTX) stock’s beta is 0.97. Other valuation ratios to consider include the price-to-book (PB) ratio at 4.71.

Financial Health

The quick ratio of Viking Therapeutics Inc. for the three months ended September 29 was 11.70, and the current ratio was 11.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Viking Therapeutics Inc.’s return on assets was -32.70%.

Earnings Surprise

For the three-month period that ended September 29, Viking Therapeutics Inc. had $125.62 million in cash. The company posted a net income of -$15.77 million in the quarter, while revenues of -$17.43 million were grew 16.04%. The analyst consensus anticipated Viking Therapeutics Inc.’s latest quarter earnings to come in at -$0.23 per share, but it turned out to be -$0.21, a 8.70% surprise. Shareholders own equity worth $76.69 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Viking Therapeutics Inc. (VKTX) price momentum. RSI 9-day as of the close on 29 December was 89.04%, suggesting the stock is Overbought, with historical volatility in this time frame at 250.18%.

As of today, VKTX’s price is $8.59 +18.12% or $1.43 from its 5-day moving average. VKTX is currently trading +130.12% higher than its 20-day SMA and +161.06% higher than its 100-day SMA. However, the stock’s current price level is +130.69% above the SMA50 and +207.59% above the SMA200.

The stochastic %K and %D were 95.12% and 95.81%, respectively, and the average true range (ATR) was 0.75. With the 14-day stochastic at 96.49% and the average true range at 0.63, the RSI (14) stands at 86.65%. The stock has reached 1.13 on the 9-day MACD Oscillator while the 14-day reading was at 2.56.

Analyst Ratings

The consensus rating for Viking Therapeutics Inc. (VKTX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell VKTX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 9 others rate it as a “buy”.

What is VKTX’s price target for the next 12 months?

Analysts predict a range of price targets between $11.00 and $30.00, with a median target of $15.00. Taking a look at these predictions, the average price target given by analysts for Viking Therapeutics Inc. (VKTX) stock is $18.33.

LEAVE A REPLY

Please enter your comment!
Please enter your name here